|
1
|
Evans WE and Relling MV: Pharmacogenomics:
Translating functional genomics into rational therapeutics.
Science. 286:487–491. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Alexov E and Sternberg M: Understanding
molecular effects of naturally occurring genetic differences. J Mol
Biol. 425:3911–3913. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Klein K, Winter S, Turpeinen M, Schwab M
and Zanger UM: Pathway-Targeted Pharmacogenomics of CYP1A2 in Human
Liver. Front Pharmacol. 1:1292010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sachse C, Brockmöller J, Bauer S and Roots
I: Functional significance of a C->A polymorphism in intron 1 of
the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin
Pharmacol. 47:445–449. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chida M, Yokoi T, Fukui T, Kinoshita M,
Yokota J and Kamataki T: Detection of three genetic polymorphisms
in the 5′-flanking region and intron 1 of human CYP1A2 in the
Japanese population. Jpn J Cancer Res. 90:899–902. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sachse C, Bhambra U, Smith G, Lightfoot
TJ, Barrett JH, Scollay J, Garner RC, Boobis AR, Wolf CR and
Gooderham NJ: Colorectal Cancer Study Group: Polymorphisms in the
cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients
and controls: Allele frequencies, linkage disequilibrium and
influence on caffeine metabolism. Br J Clin Pharmacol. 55:68–76.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dobrinas M, Cornuz J, Pedrido L and Eap
CB: Influence of cytochrome P450 oxidoreductase genetic
polymorphisms on CYP1A2 activity and inducibility by smoking.
Pharmacogenet Genomics. 22:143–151. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Perera V, Gross AS and McLachlan AJ:
Influence of environmental and genetic factors on CYP1A2 activity
in individuals of South Asian and European ancestry. Clin Pharmacol
Ther. 92:511–519. 2012.PubMed/NCBI
|
|
9
|
Ng PC and Henikoff S: SIFT: Predicting
amino acid changes that affect protein function. Nucleic Acids Res.
31:3812–3814. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu X, Jian X and Boerwinkle E: dbNSFP: A
lightweight database of human nonsynonymous SNPs and their
functional predictions. Hum Mutat. 32:894–899. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pavanello S, Fedeli U, Mastrangelo G, Rota
F, Overvad K, Raaschou-Nielsen O, Tjønneland A and Vogel U: Role of
CYP1A2 polymorphisms on lung cancer risk in a prospective study.
Cancer Genet. 205:278–284. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chida M, Yokoi T, Fukui T, Kinoshita M,
Yokota J and Kamataki T: Detection of three genetic polymorphisms
in the 5′-flanking region and intron 1 of human CYP1A2 in the
Japanese population. Jpn J Cancer Res. 90:899–902. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Han XM, Ou-Yang DS, Lu PX, Jiang CH, Shu
Y, Chen XP, Tan ZR and Zhou HH: Plasma caffeine metabolite ratio
(17X/137X) in vivo associated with G-2964A and C734A polymorphisms
of human CYP1A2. Pharmacogenetics. 11:429–435. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gunes A and Dahl ML: Variation in CYP1A2
activity and its clinical implications: Influence of environmental
factors and genetic polymorphisms. Pharmacogenomics. 9:625–637.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Browning SL, Tarekegn A, Bekele E, Bradman
N and Thomas MG: CYP1A2 is more variable than previously thought: A
genomic biography of the gene behind the human drug-metabolizing
enzyme. Pharmacogenet Genomics. 20:647–664. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
B'Chir F, Pavanello S, Knani J, Boughattas
S, Arnaud MJ and Saguem S: CYP1A2 genetic polymorphisms and
adenocarcinoma lung cancer risk in the Tunisian population. Life
Sci. 84:779–784. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hamdy SI, Hiratsuka M, Narahara K, Endo N,
El-Enany M, Moursi N, Ahmed MS and Mizugaki M: Genotyping of four
genetic polymorphisms in the CYP1A2 gene in the Egyptian
population. Br J Clin Pharmacol. 55:321–324. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Aklillu E, Carrillo JA, Makonnen E,
Hellman K, Pitarque M, Bertilsson L and Ingelman-Sundberg M:
Genetic polymorphism of CYP1A2 in Ethiopians affecting induction
and expression: Characterization of novel haplotypes with
single-nucleotide polymorphisms in intron 1. Mol Pharmacol.
64:659–669. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Djordjevic N, Ghotbi R, Jankovic S and
Aklillu E: Induction of CYP1A2 by heavy coffee consumption is
associated with the CYP1A2 −163C>A polymorphism. Eur J Clin
Pharmacol. 66:697–703. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ghotbi R, Christensen M, Roh HK,
Ingelman-Sundberg M, Aklillu E and Bertilsson L: Comparisons of
CYP1A2 genetic polymorphisms, enzyme activity and the
genotype-phenotype relationship in Swedes and Koreans. Eur J Clin
Pharmacol. 63:537–546. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Soyama A, Saito Y, Hanioka N, Maekawa K,
Komamura K, Kamakura S, Kitakaze M, Tomoike H, Ueno K, Goto Y, et
al: Single nucleotide polymorphisms and haplotypes of CYP1A2 in a
Japanese population. Drug Metab Pharmacokinet. 20:24–33. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen X, Wang L, Zhi L, Zhou G, Wang H,
Zhang X, Hao B, Zhu Y, Cheng Z and He F: The G-113A polymorphism in
CYP1A2 affects the caffeine metabolic ratio in a Chinese
population. Clin Pharmacol Ther. 78:249–259. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Myrand SP, Sekiguchi K, Man MZ, Lin X,
Tzeng RY, Teng CH, Hee B, Garrett M, Kikkawa H, Lin CY, et al:
Pharmacokinetics/genotype associations for major cytochrome P450
enzymes in native and first- and third-generation Japanese
populations: Comparison with Korean, Chinese, and Caucasian
populations. Clin Pharmacol Ther. 84:347–361. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dandara C, Lombard Z, Du Plooy I, McLellan
T, Norris SA and Ramsay M: Genetic variants in CYP (−1A2, −2C9,
−2C19, −3A4 and −3A5), VKORC1 and ABCB1 genes in a black South
African population: A window into diversity. Pharmacogenomics.
12:1663–1670. 2011. View Article : Google Scholar : PubMed/NCBI
|
